28 February 2023, Philadelphia: Dr Alison Armour, who developed PSMA617 for Endocyte, later approved as Pluvicto, today announced the launch of Curadh Clinical, a new advisory division of her US and UK based company, Curadh MTR (‘Curadh’). The firm is dedicated to improving and accelerating the development of molecularly targeted radiation therapies.
Dr Armour, CEO, and founder said, “Patients and their families have been waiting for skilled researchers to cure cancer. We are here to support the researchers. We can engage quickly, understand the very specialised needs of our clients, and provide high quality solutions to the complex challenges of modern MTR development.”
Curadh Clinical builds on Dr Armour’s previous work, as an experienced drug developer, and a proven record of successful drug approvals. She was formerly Chief Medical Officer at Endocyte, a US-based biopharmaceutical company, focused on developing targeted therapeutics for cancer treatment. While there, she successfully designed the clinical development program for Pluvicto, which was acquired by Novartis in 2018 and gained FDA approval in March 2022.
The specialised advisory team at Curadh includes Dr Colin Wheeler, a UK registered physician (MBChB) with over 25 years’ experience of Haem and Oncology drug development and regulatory roles in both the US and EU. Also joining the team are Bob Seevers, Ph.D., a former FDA reviewer, and regulatory and quality lead with 40 years of expertise in working with FDA submissions, large and small molecules, cold chain and due diligence, and Chris Clark, who brings extensive operational experience in building expert teams and companies specifically within oncology clinical research and healthcare service organizations.
Curadh Clinical offers strategic and regulatory consultation, data management and statistical services support, as well as project management of clinical operations specializing in both the strategy and delivery of early-phase clinical development.
ENDS
Notes to Editors
About Curadh Clinical:
CuradhMTR is dedicated to improving and accelerating the development of molecularly targeted radiation therapies for waiting patients.
Curadh Clinical has an experienced team focused on the new field of molecularly targeted radiation (MTR), with experts in all stages of oncology drug development and a track record of successful MTR development.
Press contact details: